CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia.

CD20-directed autologous CAR T-cell therapy in BTKi-refractory, heavily pre-treated Waldenström macroglobulinemia patients achieved an 80% CR/VGPR rate.

• Why it matters: No CAR-T therapy is approved for WM, leaving a gap in effective options for patients who have progressed on BTKi and received extensive prior treatment.
• What they did: The study evaluated safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients (ClinicalTrials.gov NCT03277729).
• The result: An 80% CR/VGPR rate suggests the approach should be tested in larger trials to further assess its potential.

AI summary of the abstract · may contain errors · not medical advice · read the paper.